CXCL12 and pulmonary arterial hypertension: Finally, we aimed to interrogate the novel influence of CXCL12 on PAH development and metabolic changes in vivo, and toward that end implanted mice with osmotic minipumps releasing a consistent dose of CXCL12 over 3 wks.